- Admin
- #1
The treatment, sotrovimab, received an emergency use authorization from the U.S. Food and Drug Administration in May, while the European Union's drug regulator has also backed it. In a study of 1,057 patients, sotrovimab resulted in a 79% reduction in risk of hospitalization for more than 24 hours or death due to any cause, the companies said on Monday. Sotrovimab belongs to a class of drugs called monoclonal antibodies that mimic the natural antibodies the body generates to fight off infection.